Kestra Medical Technologies Ltd 2024年度报告

(Mark One)☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended April 30, 2025OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934Commission File Number: 001-42549 Kestra Medical Technologies, Ltd. (Exact Name of Registrant as Specified in its Charter) Registrant’s telephone number, including area code: (425) 279-8002 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES☐NO☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES☒NO☐ Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financialreporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of theregistrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO☒As of October 31, 2024, the last business day of the Registrant’s most recently completed second fiscal quarter, there was no established public market for the Registrant’sCommon Shares. Therefore, the aggregate market value of the Registrant’s voting and non-voting common equity held by non-affiliates of the Registrant cannot be calculated. TheRegistrant’s Common Shares began trading on the Nasdaq Global Select Market on March 6, 2025.The number of shares of the Registrant’s Common Shares outstanding as of July 16, 2025 was 51,348,656. The information required by Part III of this Annual Report, to the extent not set forth herein, is incorporated herein by reference from the registrant’s definitive proxy statementrelating to the Annual Meeting to be held in 2025, which definitive proxy statement shall be filed with the Securities and Exchange Commission within 120 days after the end ofthe fiscal year to which this Annual Report relates (the “Proxy Statement”). Table of Contents PART I Item 1.Business3Item 1A.Risk Factors36Item 1B.Unresolved Staff Comments90Item 1C.Cybersecurity90Item 2.Properties91Item 3.Legal Proceedings92Item 4.Mine Safety Disclosures92 PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities93Item 6.[Reserved]93Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations94Item 7A.Quantitative and Qualitative Disclosures About Market Risk107Item 8.Financial Statements and Supplementary Data107Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure107Item 9A.Controls and Procedures107Item 9B.Other Information109Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections109 PART III Item 10.Directors, Executive Officers and Corporate Governance110Item 11.Executive Compensation110Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters110Item 13.Certain Relationships and Related Transactions, and Director Independence110Item 14.Principal Accounting Fees and Services110 PART IV Item 15.Exhibits, Financial Statement Schedules111Item 16.Form 10-K Summary111 Explanatory Note On March 7, 2025, Kestra Medical Technologies, Ltd. completed its initial public offering of its Common Shares, par value$1.00 per share (the “Common Shares”). Kestra Medical Technologies, Ltd. was formed solely for the purpose of completing theinitial public offering and prior to the consummation of the initial public offering, did not engage in any business or activities otherthan those incidental to its formation